アテローム性動脈硬化症治療薬の世界市場-2024-2031

概要

世界のアテローム性動脈硬化症治療薬市場は、2023年に264億米ドルに達し、2024-2031年の予測期間中にCAGR 2.6％で成長し、2031年には325億米ドルに達すると予測されています。

アテローム性動脈硬化症とは、動脈壁に脂肪、コレステロール、その他の物質が蓄積することです。この蓄積はプラークと呼ばれます。プラークは動脈を狭窄させ、血流を阻害します。また、プラークが破裂して血栓ができることもあります。アテローム性動脈硬化症は心臓の問題と思われがちですが、体中の動脈に影響を及ぼす可能性があります。アテローム性動脈硬化症は治療することができます。健康的な生活習慣は動脈硬化の予防に役立ちます。

市場は、アテローム性動脈硬化症および心血管疾患の有病率の増加、心血管疾患に対する意識の高まりなどの要因によって牽引されています。アテローム性動脈硬化症に使用される薬剤は、抗血小板・抗凝固薬、コレステロール低下薬、ACE阻害薬、フィブリン酸およびオメガ3脂肪酸誘導体、ベータ遮断薬などです。

市場力学：

促進要因

心血管疾患および動脈硬化性疾患の有病率の増加

世界のアテローム性動脈硬化症治療薬市場の需要は、複数の要因によって牽引されています。主な要因の1つは、心血管疾患および動脈硬化性疾患の有病率の増加です。CVDは心臓や血管の疾患群で、アテローム性動脈硬化症、冠動脈性心疾患、脳血管疾患、リウマチ性心疾患などが含まれます。CVDによる死亡の5人に4人以上は心臓発作と脳卒中によるもので、その3分の1は70歳未満の早死にです。

MDPIが2023年10月に発表した調査報告書によると、心血管疾患（CVD）は世界の死因の第1位であり、毎年1,670万人が死亡しています。動脈硬化の有病率は世界的に増加しており、循環器疾患患者の50％以上が動脈硬化で死亡しています。

アテローム性動脈硬化症は心血管系疾患の主な根本原因であり、心臓発作や脳卒中のリスク増大と関連しており、CVDによる全死亡の85％を占めています。2022年6月のJAMAネットワークによると、一般人口におけるアテローム性動脈硬化症の有病率と負担はいくつかの研究で報告されており、多血管アテローム性動脈硬化症の推定値は3％から42％です。同様に、2021年9月のAHAジャーナルでは、アテローム性動脈硬化症の有病率は女性よりも男性で1.9倍高く、男女ともに年齢とともに急激に増加すると述べています。

さらに、主な企業は研究開発に力を入れており、CVD疾患の臨床試験件数が増加していることも、この市場の成長を促進すると思われます。例えば、2024年4月、New Amsterdam Pharma Company N.V.は、最大耐用脂質低下療法を受けているにもかかわらずLDL-Cが十分にコントロールされていないアテローム性動脈硬化性心血管疾患（「ASCVD」）の既往歴のある成人患者を対象にオビセトラピブを評価する極めて重要な第3相PREVAIL心血管アウトカム試験（「CVOT」）の登録目標患者数9,000人を達成したと発表しました。

また2023年8月、メルクは経口プロテイン転換酵素サブチリシン/ケキシン9型（PCSK9）阻害薬MK-0616の第3相臨床プログラムCORAL reefの開始を発表し、成人の高コレステロール血症治療薬として評価中です。

阻害要因

製品回収、治療に伴う高コスト、薬剤に伴うリスクと副作用、個人の認識不足、厳しい規制政策、高度医療インフラの欠如、診断率の低さ、ジェネリック医薬品の利用可能性などの要因が市場の妨げになると予想されます。

このレポートの詳細について- サンプル請求

目次

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 動脈硬化および心血管疾患の有病率の増加
    • 心血管疾患に対する意識の高まり
  • 抑制要因
    • 製品回収
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 薬剤タイプ別

• 抗血小板薬・抗凝固薬
• コレステロール低下薬
• ACE阻害剤
• 繊維酸とオメガ3脂肪酸誘導体
• ベータ遮断薬
• その他

第7章 投与経路別

• 経口
• 注射剤

第8章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• Pfizer Inc
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• AstraZeneca
• Merck & Co., Inc.
• Amgen Inc
• Novartis AG
• Eli Lilly and Company
• GSK plc
• Bayer AG
• CSL
• New Amsterdam Pharma Company N.V.

第12章 付録

Overview

The global atherosclerosis drugs market reached US$ 26.4 billion in 2023 and is expected to reach US$ 32.5 billion by 2031 growing with a CAGR of 2.6% during the forecast period 2024-2031.

Atherosclerosis is the buildup of fats, cholesterol, and other substances in and on the artery walls. This buildup is called plaque. The plaque can cause arteries to narrow, blocking blood flow. The plaque can also burst, leading to a blood clot. Although atherosclerosis is often considered a heart problem, it can affect arteries anywhere in the body. Atherosclerosis can be treated. Healthy lifestyle habits can help prevent atherosclerosis.

The market is driven by factors such as the increase in the prevalence of atherosclerosis & cardiovascular diseases and rising awareness about cardiovascular diseases. Drugs used in atherosclerosis are anti-platelet & anticoagulants, cholesterol-lowering medication, ACE inhibitors, fibric acid and omega-3 fatty acid derivatives, beta-blockers, and others.

Market Dynamics: Drivers

Increase in prevalence of cardiovascular & atherosclerosis diseases

The demand for the global atherosclerosis drugs market is driven by multiple factors. One of the primary factors is the increase in the prevalence of cardiovascular & atherosclerosis diseases. CVDs are a group of disorders of the heart and blood vessels and include atherosclerosis, coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other conditions. More than four out of five CVD deaths are due to heart attacks and strokes, and one-third of these deaths occur prematurely in people under 70 years of age.

According to the MDPI research publication in October 2023, Cardiovascular diseases (CVDs) are the leading cause of death globally, accounting for 16.7 million deaths each year. The prevalence of atherosclerosis is increasing worldwide and more than 50% of people with circulatory disease die of it, mostly in modern societies.

Atherosclerosis is the main underlying cause of cardiovascular disease and is linked to an increased risk of heart attack and stroke, representing 85% of all deaths from CVD. As per the JAMA network in June 2022, the prevalence and burden of atherosclerosis in the general population have been reported in several studies, and the estimate of polyvascular atherosclerosis ranges from 3% to 42%. Similarly, AHA journals in September 2021, stated that the prevalence of atherosclerosis was 1.9 times higher in men than in women and increased sharply with age in both sexes.

Moreover, key players are more focused on the research & developments and the rising number of clinical trials in the CVD diseases would propel this market growth. For instance, in April 2024, New Amsterdam Pharma Company N.V. announced that it had met the enrollment target of 9,000 patients for the pivotal Phase 3 PREVAIL cardiovascular outcomes trial ("CVOT") evaluating obicetrapib in adult patients with a history of atherosclerotic cardiovascular disease ("ASCVD"), who's LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.

Also, in August 2023, Merck announced the initiation of the company's Phase 3 clinical program, CORAL reef, for MK-0616, an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, being evaluated for the treatment of adults with hypercholesterolemia.

Restraints

Factors such as product recalls, high cost associated with the treatment, risk & side effects associated with the drugs, lack of awareness among individuals, stringent regulatory policies, lack of advanced healthcare infrastructure, low diagnosis rate, and availability of generic drugs, are expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global atherosclerosis drugs market is segmented based on drug type, route of administration, distribution channels, and region.

The cholesterol-lowering medication segment accounted for approximately 54.5% of the global atherosclerosis drugs market share

The cholesterol-lowering medication segment is expected to hold the largest market share over the forecast period. Cholesterol-lowering medications, particularly statins, are a mainstay of atherosclerosis treatment as they help reduce the buildup of plaque in arteries by lowering LDL ("bad") cholesterol levels.

Statins are commonly used to lower cholesterol, improve artery health, and prevent atherosclerosis. There are many other types of cholesterol-lowering drugs. They include niacin, fibrates, and bile acid sequestrants.

Moreover, key players in the industry more focus on research & development studies and getting positive results from the clinical trials in the CVD diseases that would propel this segment growth in this region. For instance, in February 2024, a research team based at the Centro National de Investigations Cardiovascular (CNIC) in Madrid and Aarhus University in Denmark identified an important mechanism that can result in the regression, or shrinkage, of atherosclerotic plaques. The study identifies cells derived from the smooth muscle cells in the arterial wall as a new target for future therapies.

According to Clinical Trials Arena in April 2024, Repatha (evolocumab) is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) for lowering cholesterol in patients. It is indicated to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease (CVD).

Similarly, in May 2024, LIB Therapeutics announces positive Lerodalcibep results from two phase 3 LIBerate studies at the 92nd European Atherosclerosis Society Congress. In addition, key player's product approvals help to drive this segment's growth. For instance, in July 2023, - Novartis announced that the US Food and Drug Administration (FDA) has approved a label update for Leqvio (inclisiran) to enable earlier use in patients with elevated LDL-C who have an increased risk of heart disease, as an adjunct to diet and statin therapy. This patient population includes those who have comorbidities such as hypertension and diabetes and have not yet had a first cardiovascular event.

Geographical Analysis

North America accounted for approximately 41.2% of the global atherosclerosis drugs market share

North America region is expected to hold the largest market share over the forecast period. Heart disease has been the leading cause of death in the United States. According to the CDC's heart disease facts in May 2024, one person dies every 33 seconds from cardiovascular disease. About 695,000 people died from heart disease in 2021-that's 1 in every 5 deaths. Every year, about 805,000 people in the United States have a heart attack.

Obesity or overweight affects approximately 70% of American adults. Obesity and overweight are serious health issues that increase the risk for premature death and a variety of health problems, including heart attack and stroke.

Moreover, a major number of key players' presence, well-advanced healthcare infrastructure, and product launches & approvals would propel this market growth in this region. For instance, in December 2021, Novartis announced the US Food and Drug Administration (FDA) approval of Leqvio (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C) with two doses a year, after an initial dose and one at three months.

Also, in February 2021, Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved EvkeezaTM (evinacumab-dgnb) as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat adult and pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). Evkeeza is the first FDA-approved treatment that binds to and blocks the function of angiopoietin-like 3 (ANGPTL3), a protein that plays a key role in lipid metabolism.

Market Segmentation

By Drug Type

• Anti-platelet & Anticoagulants
• Cholesterol Lowering Medication
• ACE Inhibitors
• Fibric Acid and Omega-3 Fatty Acid Derivatives
• Beta Blockers
• Others

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the atherosclerosis drugs market include Pfizer Inc, AstraZeneca, Merck & Co., Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, GSK plc, Bayer AG, CSL and New Amsterdam Pharma Company N.V. among others.

Key Developments

• In March 2024, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight.
• In June 2023, AGEPHA Pharma USA, LLC, announced that, following a Priority Review, the U.S. Food and Drug Administration (FDA) has approved LODOCO as the first anti-inflammatory atheroprotective cardiovascular treatment demonstrated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease.

Why Purchase the Report?

• To visualize the global atherosclerosis drugs market segmentation based on drug type, Route of Administration, distribution channels, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the antinauseant drugs market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.

The global atherosclerosis drugs market report would provide approximately 62 tables, 59 figures, and 183 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Type
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by Distribution Channels
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increase in Prevalence of Atherosclerosis & Cardiovascular Diseases
    • 4.1.1.2. Rising Awareness about Cardiovascular Diseases
  • 4.1.2. Restraints
    • 4.1.2.1. Product Recalls
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. By Drug Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 6.1.2. Market Attractiveness Index, By Drug Type
• 6.2. Anti-platelet & Anticoagulants *
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Cholesterol Lowering Medication
• 6.4. ACE Inhibitors
• 6.5. Fibric Acid and Omega-3 Fatty Acid Derivatives
• 6.6. Beta Blockers
• 6.7. Others

7. By Route of Administration

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration Market Attractiveness Index, By Route of Administration
• 7.2. Oral *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Injectable

8. By Distribution Channels

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 8.1.2. Market Attractiveness Index, By Distribution Channels
• 8.2. Hospital Pharmacies *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Retail Pharmacies
• 8.4. Online Pharmacies

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Pfizer Inc *
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. AstraZeneca
• 11.3. Merck & Co., Inc.
• 11.4. Amgen Inc
• 11.5. Novartis AG
• 11.6. Eli Lilly and Company
• 11.7. GSK plc
• 11.8. Bayer AG
• 11.9. CSL
• 11.10. New Amsterdam Pharma Company N.V.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us